Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

High-Dose Rate Brachytherapy Boost with Stereotactic Radiation Body Therapy to the Prostate and Pelvic Lymph Nodes for the Treatment of Unfavorable Intermediate or Higher Risk Prostate Cancer

Trial Status: active

This phase I/II trial tests the safety and effectiveness of high-dose rate (HDR) brachytherapy boost with stereotactic radiation body therapy (SBRT) to the prostate and pelvic lymph nodes for treating patients with unfavorable intermediate or higher risk prostate cancer. HDR brachytherapy, also known as internal radiation therapy, uses high doses of radioactive material placed directly into or near a tumor to kill tumor cells. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. HDR brachytherapy boost with SBRT may be a safe and effective approach in the treatment of patients with unfavorable intermediate or higher risk prostate cancer.